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INTRODUCTION
Neurotoxicity, especially peripheral neuropathy, is a com-
mon adverse effect of cytotoxic chemotherapeutic agents, but
central nervous system (CNS) toxicity is relatively uncom-
mon. 5-Fluorouracil (5-FU), a fluorinated pyrimidine, is an
antineoplastic antimetabolite first introduced in 1958 that
is used in the treatment of various solid cancers such as car-
cinoma of the colon, rectum, breast, stomach, and pancreas
(1). This fluorinated pyrimidine is metabolized inside the
cells to 5-fluoro-2-deoxyuridine-5-phosphate, which inhibits
thymidylate synthase. Blockade of this enzyme inhibits DNA
synthesis. Common side effects of 5-FU are related to its effects
on the bone marrow (leukopenia) and gastrointestinal epithe-
lium (stomatitis, esophagopharyngitis, diarrhea, anorexia,
nausea, vomiting) (2). However, neurotoxicity is uncommon
with 5-FU-based chemotherapy (3). Wernicke’s encephalopa-
thy, an acute neuropsychiatric syndrome that results from
thiamine deficiency, has rarely been associated with 5-FU
treatment. Here, we report a patient who developed imag-
ing-documented Wernicke’s encephalopathy following 5-
FU-based chemotherapy and who recovered after stopping
therapy.
CASE REPORT
A 46-yr-old woman was diagnosed with nasopharyngeal
cancer 5 months before being admitted to our hospital for a
course of chemotherapy. She had no history of chronic alco-
hol consumption or benzodiazepine addiction, or any other
significant medical history including malnutrition, surgery
or herbal medications. There were no laboratory abnormali-
ties. Concurrent chemoradiation therapy was performed with
cisplatin (100 mg/m2 at 3-week intervals). One month after
the completion of concurrent chemoradiation therapy, we gave
her chemotherapy consisting of a continuous infusion of 5-
FU 1,000 mg/m2/day for 4 days and cisplatin 75 mg/m2 for
1 hr on the first day of each chemotherapy cycle at 3-week
intervals. She experienced NCI CTC (v. 3.0) grade 2 stom-
atitis and grade 3 neutropenia during the first cycle, which
resolved after supportive therapy. There was no diarrhea or
vomiting of significant grade.
On the 20th day of the second round of chemotherapy with
5-FU and cisplatin, she experienced dizziness with nystag-
mus, but these symptoms resolved with conservative man-
agement. Fifteen days after the dizziness episode, she showed
acute onset disorientation, headache, and lethargy. Her men-
tal status showed confusion, but neither focal neurological
signs nor pathological reflexes were noted. Her blood pres-
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A Case of Wernicke’ s Encephalopathy Following Fluorouracil-based
Chemotherapy
The pyrimidine antimetabolite 5-fluorouracil (5-FU) is a chemotherapeutic agent
used widely for various tumors. Common side effects of 5-FU are related to its effects
on the bone marrow and gastrointestinal epithelium. Neurotoxicity caused by 5-FU
is uncommon, although acute and delayed forms have been reported. Wernicke’s
encephalopathy is an acute, neuropsychiatric syndrome resulting from thiamine de-
ficiency, and has significant morbidity and mortality. Central nervous system neu-
rotoxicity such as Wernicke’s encephalopathy following chemotherapy with 5-FU
has been reported rarely, although it has been suggested that 5-FU can produce
adverse neurological effects by causing thiamine deficiency. We report a patient
with Wernicke’s encephalopathy, reversible with thiamine therapy, associated with
5-FU-based chemotherapy.
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Accepted : 4 April 2008sure was 110/70 mmHg, pulse rate 110/min, respiratory rate
14/min, and body temperature 36.4℃. Her myelosuppre-
ssion status after chemotherapy was a white blood cell count
of 1,300/μ L (neutrophils 74.4%, lymphocytes 14.3%), hemo-
globin concentration of 8.1 g/dL, and platelet count of 62,000/
μ L. At that time, the level of serum BUN and creatinine were
10 mg/dL and 0.6 mg/dL. Her serum sodium and potassi-
um were 133 and 3.5 mM/L, respectively. The total protein
was 5.8 g/dL (reference range, 6.5-8.4 g/dL), serum albumin
3.6 g/dL (reference range, 3.5-5.1 g/ dL), triglyceride 67 mg/
dL (reference range, 28-150 mg/dL), cholesterol 68 mg/dL
(reference range, 130-240 mg/dL), and magnesium 1.9 mg/dL
(reference range, 1.9-3.1 mg/dL). The body weight of the pa-
tient at diagnosis was 52 kg and was 54 kg at the time of this
event. Her serum folic acid concentration was 2 ng/mL (ref-
erence range, 3-17 ng/mL), vitamin B12 concentration 1,259
pg/mL (reference range, 253-1,090 pg/mL), and thiamine
concentration 138.1 ng/dL (reference range, 21.3-81.9 ng/dL).
The ammonia concentration was normal. Brain magnetic res-
onance imaging (MRI) showed symmetrical high signal inten-
sities in the posterior aspect of the medulla and periaqueduc-
tal area of the midbrain that were consistent with Wernicke’s
encephalopathy. A small amount of subdural hematoma in
the right posterior occipital area was noted (Fig. 1A). She was
given intravenous thiamine, 500 mg for 5 days, and then oral
thiamine, 60 mg/day, even though the initial serum thiamine
level was normal. Her confused mental state resolved after
several hours, and her dizziness and nystagmus gradually im-
proved over the next 5 days.
The brain MRI was repeated in the outpatient clinic 1 mo-
nth after the episode. The MRI showed nearly complete res-
olution of the previous abnormal signal intensities in the pos-
terior aspect of the medulla and the periaqueductal area of
the midbrain, including the subdural hematoma (Fig. 1B).
DISCUSSION
Neurotoxicity is an uncommon side effect of 5-FU thera-
py. There are two types of toxicity, classified according to the
time of onset of symptoms. Acute toxicity manifests as a dif-
fuse encephalopathy or a cerebellar syndrome, is dose-relat-
ed, and is generally self-limiting. Delayed toxicity appears
several months later, is characterized as subacute multifocal
leukoencephalopathy, is immune-mediated, and responds to
corticosteroid treatment (3, 4). About 5% (range, 0.6-7%)
of patients treated with 5-FU experience neurotoxicity (3).
In a study by Yeh and Cheng, 5.57% of patients developed
5-FU-related encephalopathy (5).
Wernicke’s encephalopathy is characterized by an acute
onset of symptoms that may include changes in mental sta-
tus, ocular abnormalities and motor problems such as unco-
ordinated gait and ataxia, but this triad of symptoms is seen
in only 16% of patients (6). Wernicke’s encephalopathy can
be caused by thiamine deficiency associated with chronic alco-
hol abuse, malnutrition or unbalanced nutrition, gastrointesti-
nal surgery, recurrent vomiting, chronic diarrhea, systemic
illness, or magnesium depletion, all of which can affect thi-
amine uptake and utilization (7-9). Wernicke’s encephalopa-
thy can be diagnosed primarily from the clinical features, and
it should be confirmed by symptomatic improvement with
thiamine treatment (10). MRI is currently considered the
most valuable method to confirm a diagnosis of Wernicke’s
encephalopathy. MRI has a sensitivity of 53% and a high sp-
ecificity of 93%, so it can be used to rule out other disorders.
In Wernicke’s encephalopathy, MRI studies typically show
an increased T2 signal that is bilaterally symmetrical in the
paraventricular regions of the thalamus, the hypothalamus,
mammillary bodies, the periaqueductal region, the floor of
the fourth ventricle, and the midline cerebellum (6).
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Fig. 1. (A) The initial MRI demonstrates
symmetric high signal intensities in the
posterior aspect of the medulla and the
periaqueductal area of the midbrain (nar-
row arrows) and an occipitoparietal hem-
atoma (broad arrows). Axial FLAIR. (B)
Follow-up MRI 1 month later shows nearly
complete resolution of the previous abnor-
mal signal intensities in the posterior as-
pect of the medulla, the periaqueductal
area of the midbrain, and the occipitopari-
etal hematoma.
A
BWernicke’s encephalopathy following chemotherapy with
5-FU has been reported rarely (11). Although the biochem-
ical basis for the neurological toxicity of 5-FU is not fully
understood, it may be related to blockade of the Krebs cycle
by fluoroacetate, a product of fluorouracil catabolism; anoth-
er possibility relates to thiamine deficiency. Either possibili-
ty means that 5-FU-induced CNS neurotoxicity can manifest
as Wernicke’s encephalopathy. Thiamine phosphate is the
active form of the vitamin, but its formation from thiamine
can be blocked by 5-FU, an action that could further exac-
erbate preexisting thiamine deficiency in cancer patients (3).
Askoy et al. prospectively followed 35 patients receiving 5-
FU-based chemotherapy and treated thiamine-deficient pa-
tients with vitamin supplements (12).
Historically, most 5-FU-associated neuropathies developed
during 5-FU infusion or shortly after 5-FU completion. Our
patient developed Wernicke’s encephalopathy after 5 weeks
of initial 5-FU exposure, but at that time, the concentration
of thiamine was not low, although this measurement is lim-
ited by a lack of specificity and technical difficulties (6). The
nutritional status of our patient was improving after several
weeks, although her nutritional intake remained lower than
normal because of mouth dryness induced by the previous
concurrent chemoradiation of the head and neck cancer. It
appears that the 5-FU could have caused the Wernicke’s en-
cephalopathy in our patient despite the small dietary deficien-
cy, because she was not in severe malnutritional status judg-
ing from the total protein, albumin, triglyceride, and mag-
nesium levels and her relatively improving appetite. A defi-
ciency in dihydropyrimidine dehydrogenase (DPD), the rate-
limiting enzyme responsible for the catabolism of 5-FU, may
be associated with this type of neurotoxicity, gastrointesti-
nal toxicity, and myelosuppression (4). We did not measure
the DPD level in this patient, but the concurrent myelosup-
pression might reflect her low DPD level indirectly. In addi-
tion, cisplatin combined with 5-FU can induce neurotoxici-
ty, but this complication manifests mainly as a peripheral
sensory neuropathy, although it may occasionally induce en-
cephalopathy with or without seizure (13), and it has not been
reported in relation to thiamine. Our patient was given a
higher dose of cisplatin in a previous concurrent chemoradi-
ation stage, but this did not produce any neurological abnor-
mality.
We postulate that this patient had barely escaped the ma-
rginal thiamine deficiency during cancer and therapy, and
the subsequent exposure to 5-FU aggravated the dietary im-
balance and caused the encephalopathy. The clinical neuro-
logical symptoms and radiological abnormalities were reve-
rsed with adequate replacement of thiamine, which differs
somewhat from traditional Wernicke’s encephalopathy. Some
therapies for malignancy have induced Wernicke’s encepha-
lopathy caused by a lack of thiamine supplementation with
total parenteral nutrition, fast-growing neoplastic cells, vom-
iting and poor appetite. Moreover the use of specific chemo-
therapy agents such as 5-FU and ifosfamide can induce this
neurological disorder (6, 14). Thus, it is important to confirm
the clinical suspicion of Wernicke’s encephalopathy associ-
ated with thiamine deficiency in treating cancer patients.
In conclusion, physicians should be aware of neurological
signs in cancer patients treated with 5-FU, regardless of the
CNS involvement of the tumor, especially if the patient is
at risk of dietary deficiency.
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